1 Original Article 2 3 Long-term Air Pollution Exposure are Associated with Higher Incidence of ST-4 elevation Myocardial Infarction and In-hospital Cardiogenic Shock 5 Jinah Cha, BS^{1,3*}, Se Yeon Choi, PhD^{2*}, Seung-Woon Rha, MD, PhD^{1,3}, Byoung Geol Choi, 6 PhD². Jae Kyeong Byun, PhD², Sujin Hyun, BS⁴, Min Woo Lee, PhD⁵, Jaeho Kang, MD³, 7 Wonsang Chu, MD³, Soohyung Park, MD³, Eun Jin Park, MD, PhD³, Dong Oh Kang, MD, 8 PhD³, Cheol Ung Choi, MD, PhD³, Suhng Wook Kim, PhD⁶, Myung ho Jeong, MD, PhD⁷ 10 and the other Korea Acute Myocardial Infarction Registry (KAMIR) investigators 11 12 ¹BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of 13 Medicine, Seoul, Republic of Korea; 14 ²Cardiovascular Research Institution, Korea University College of Medicine, Seoul, Republic 15 of Korea; 16 ³ Department of Cardiology, Cardiovascular Center, Guro Hospital, Korea University College 17 of Medicine, Seoul, Republic of Korea; 18 ⁴Transdisciplinary Major in Learning Health Systems, Department of Healthcare Sciences, 19 Graduate School, Korea University; 20 ⁵Research Institute of Health Science, Korea University, Seoul, Korea; 21 ⁶School of Health and Environmental Science, College of Health Sciences, Korea University, 22 Seoul, Korea; 23 ⁷Department of Cardiology, Cardiovascular Center, Chonnam National University Hospital, 24 Gwangju, Republic of Korea.

* The first two authors (J Cha and SY Choi) contributed equally to this article.
Short title: Impact of Long-term Air Pollution Exposure on AMI
Correspondence to: Seung-Woon Rha, MD, Ph.D.;
Cardiovascular Center,
Korea University Guro Hospital,
148, Gurodong-ro, Guro-gu, Seoul 08308, Korea;

32 Tel.: +82-2-2626-3020;

25

33 Fax: +82-2-864-3062;

34 E-mail: swrha617@yahoo.co.kr

35 Total word count: 5,687

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

severe cardiovascular complications.

Abstract **Background:** Previous studies have reported the association between myocardial infarction (MI) and air pollution (AP). However, limited information is available regarding the longterm effects of AP on the relative incidence rates of ST-elevation MI (STEMI) and Non-STelevation MI (NSTEMI). Methods: Study subjects were enrolled from the Korea Acute MI registry (KAMIR) and KAMIR-National Institutes of Health (NIH). A total of 45,619 eligible patients with AMI were enrolled between January 2006 and December 2015. We investigated the association between long-term exposure to AP and compared the incidence of STEMI with those of NSTEMI. Mixed-effect regression models were used to examine the association between the annual average ambient AP before MI onset and the incidence of STEMI compared with that of NSTEMI, and to evaluate the association of AP with the incidence of in-hospital cardiogenic shock. **Results:** After mixed-effect regression model analysis, each 1 µg/m³ increase in particulate matter (PM) 10 μm or less in diameter (PM₁₀) was associated with increased incidence of STEMI compared with NSTEMI (odds ratio [OR]:1.009, 95% Confidence Interval [CI]: 1.002–1.016; p = 0.012). For in-hospital cardiogenic shock complication, each 1 μ g/m³ increase in PM₁₀ and 1 part per billion increase in SO₂ were associated with increased risk, PM_{10} (OR:1.033, 95% CI, 1.018–1.050; p < 0.001), SO_2 (OR:1.104, 95% CI, 1.006–1.212; p = 0.037), respectively. Conclusion: A high concentration of air pollutants, particularly PM₁₀, was an environmental risk factor for an increase incidence of development of STEMI. PM₁₀ and SO₂ were found to be risk factors for in-hospital cardiogenic shock complications. Policy-level strategies and clinical efforts to reduce AP exposure are necessary to prevent the incidence of STEMI and

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Key Words: Air pollution, Particulate matter, Myocardial infarction, Cardiogenic Shock **Clinical Perspective** What is new? This study determined the long-term association between air pollutants and the relative incidence of STEMI and NSTEMI using a large patient registry dataset. Air pollution, particularly involving PM₁₀, was associated with an increased risk of STEMI compared with NSTEMI. In patients with Acute Myocardial Infarction (AMI), PM₁₀ and SO₂ were found to be risk factors for the development of in-hospital cardiogenic shock complications. What are the clinical implications? The findings of this study should be considered a milestone in developing a policy to reduce AP exposure and prevent STEMI incidence in high-risk MI patients. Clinical efforts are necessary to reduce the incidence rates of adverse cardiovascular complications such as cardiogenic shock. Mixed-effect regression model analysis for AP exposure is useful in providing information that can enable early identification of STEMI patients and those with severe complication cardiogenic shock risks.

Non-standard Abbreviations and Acronyms

ACS acute coronary syndrome AMI acute myocardial infarction

AP air pollution BMI body mass index

81

82

83

84

85

86

87

88

89

CAD coronary artery disease
CI confidence intervals
CO carbon monoxide

CVA cerebrovascular disease

DL dyslipidemia
DM diabetes mellitus
HF heart failure
HTN hypertension

IHD Ischemic heart diseases

LVEF left ventricular ejection fraction

MI myocardial infarction

MVD multivessel coronary artery disease

NO₂ nitric dioxide

NSTEMI Non-ST-elevation myocardial infarction

 ${
m O}_3$ ozone OR odds ratios

PCI percutaneous coronary intervention

 PM_{10} particulate matter 10 μm or less in diameter $PM_{2.5}$ particulate matter 2.5 μm or less in diameter

ppm part per million SO₂ sulfur dioxide

STEMI ST-elevation myocardial infarction

Introduction

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

Ischemic heart diseases (IHD) including acute myocardial infarction (AMI) are a public health burden and are a leading cause of mortality and morbidity worldwide. AMI is a major cause of mortality in the Asia-Pacific region.¹⁻⁴ In particular, in patients with coronary artery disease (CAD), air pollution (AP) is related to complications such as increased hospitalization, re-admission, and early mortality. 5-7 Exposure to highly polluted air is one of the environmental factors that triggers AMI.8 There is a relationship between short and longterm effects of exposure to AP; however, long-term exposure effects outnumber the sum of all short-term effects. 9 Most of the studies have focused on the association between the effects of short-term exposure to AP and AMI. 8, 10, 11 Our previous studies demonstrated that AP exposure was associated with overall adverse clinical outcomes, including mortality, in AMI patients based on short and long-term exposure and follow-up periods. ^{12, 13} However, only few studies have reported on long-term AP exposure along with comparison between the relative incidence of ST-elevation myocardial infarction(MI, STEMI) and that of Non-STelevation myocardial infarction (Non-STEMI) and associated adverse effects related to mortality. This study is an extension of our previous study and aimed to clarify the association between the long-term average concentration of AP and the relative risk of developing a STEMI compared to a NSTEMI, as well as the relationship between the annual average concentration of AP and cardiogenic shock, which was observed to be high in STEMI patients.

Methods

Study Protocols and Population

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

The study subjects were enrolled in the Korea AMI registry (KAMIR) and KAMIR-National Institutes of Health (NIH). The KAMIR study protocol has been introduced previously. 14 KAMIR and KAMIR-NIH are nationwide prospective multicenter registration study series that aim to establish treatment guidelines and derive risk factors through the analysis of various clinical characteristics and follow-up of Korean AMI patients since October 2005 onwards. A flowchart of the study is shown in Figure 1. A total of 50,130 patients with AMI were enrolled in the KAMIR and KAMIR-NIH between January 2006 and December 2015. The exclusion criteria were as follows: (1) date of symptom onset before 2006, (2) missing date of symptom onset, (3) age < 18 years, and (4) no final diagnosis of MI at discharge. **Ethics approval** This study was approved by the Institutional Review Board (IRB) of Korea University Guro Hospital (KUGH, #2016GR0740) and was conducted in accordance with the principles of the Declaration of Helsinki. AP measurement Hourly AP concentrations were provided by the Korean Ministry of Environment (http://www.airkorea.or.kr). In 2001, 329 monitoring stations nationwide began measuring the concentration of air pollutants. Measurement of air pollutants involved the β-ray absorption method for particulate matter (PM) 10 um or less in diameter (PM₁₀), the nondispersive infrared method for carbon monoxide (CO), the pulse ultraviolet fluorescence method for sulfur dioxide (SO₂), the chemiluminescence method for nitric dioxide (NO₂), and the ultraviolet photometric method for ozone (O₃). The concentration measurement of PM 2.5 μm or less in diameter (PM_{2.5}) began in January 2015; therefore, annual average

concentration values were not available during the patient enrollment period (2006–2015) and was excluded.

We transformed collected data into the daily average value, and then, the annual average value of air pollutants before the symptom day was calculated the way previous research was performed. ¹³ Each monitoring station was matched by the closest distance in a straight line to 68 hospitals registered in KAMIR to measure individual exposure concentration of air pollutants. Monitoring stations were selected based on hospital admission addresses for the following reasons: (1) Patient addresses were not included in the multicenter registry data. (2) As AMI is an emergency, it is assumed that the patient was admitted to an emergency room close to the workplace and residence at the time of symptom onset. If a pollutant measurement was missed due to a connection error with a monitoring station, the measurement of the next-nearest monitoring station was assigned. Symptom date was defined as the first occurrence of MI-related symptoms such as chest pain or dyspnea.

Study Definitions

The diagnosis of AMI was defined as an elevation in cardiac biomarkers (creatinine kinase-MB, and troponin I, or T) with typical changes on 12 leads electrocardiogram (ECG) or clinical symptoms. STEMI was diagnosed as a new ST-elevation segment measuring ≥1 mm from ≥2 contiguous leads on ECG. Patients with positive cardiac biomarkers but without ECG findings of STEMI were defined as NSTEMI. Cardiogenic shock was defined as a systolic blood pressure <90 mmHg for >30 min, the need for supportive management to maintain systolic blood pressure >90 mmHg, and clinical signs of pulmonary congestion.

Individual cardiovascular risk factors, including hypertension (HTN), dyslipidemia (DL), diabetes mellitus (DM), prior cardiovascular disease, heart failure (HF), prior cerebrovascular disease (CVA), and smoking history, were based on self reports by the patient.

Statistical Analysis

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

All statistical analyses were performed using R version 4.1.2. (R Core Team, 2021; R: Language and Environment for Statistical Computing; R Foundation for Statistical Computing, Vienna, Austria, URL: https://www.R-project.org/). We compared the clinical and angiographic characteristics using a X² test or Fisher's exact test for categorical variables and Student's t-test or Mann-Whitney rank test for continuous variables. Categorical data were expressed as percentages, and continuous variables were described as mean \pm standard deviation. We used generalized logistic mixed effect models with a random effect term for hospitals to examine the associations of each air pollutant with the incidence rate of STEMI and cardiogenic shock complication rates, and to account for hospital and regional effects such as accessibility and treatment plans. Using a multivariable model, we adjusted for potential confounding factors including: age, sex, body mass index (BMI), smoking status, HTN, DM, DL, stroke, HF, previous IHD, and symptom date. STEMI status, percutaneous coronary intervention (PCI), and left ventricular ejection fraction (LVEF), were used to analyze the incidence of cardiogenic shock complications. In the subgroup analysis, several stratified analyses were performed to test the potential effect modifications of the following factors, by including an interaction term: for the STEMI group analysis, the following terms were used: age, sex, HTN, DM, DL, CVA, HF, prior IHD, smoking, family history of CAD. In the cardiogenic shock group, STEMI status, PCI, and LVEF were added. The results were presented as adjusted odds ratios (OR) for logistic regression with corresponding 95% confidence intervals (CI). Statistical significance was defined as a p-value < 0.05.

Results

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

A total of 45,619 patients with AMI were enrolled in our study. Of these, 20,526 were patients with NSTEMI and 25,093 were patients with STEMI. In our study population, compared with patients with NSTEMI, patients with STEMI were younger, male, had a higher smoking status, and had fewer underlying chronic diseases, such as DM, HTN, and DL. Moreover, patients with STEMI had more Killip class IV and a low LVEF and those were less likely to have a history of cardiovascular diseases, such as HF, CVA, and previous IHD. Among the angiographic parameters, the STEMI group had more PCI as the initial treatment for MI, lower multivessel coronary artery disease (MVD), and the left main artery as the culprit lesion. The cardiogenic shock complication rate during the index hospitalization was significantly higher in the STEMI group (Table 1). Therefore, we analyzed the link between cardiogenic shock events, which are severe cardiovascular complications, and annual AP exposure (Table 4). In Table 2, we observed the median value of annual average concentrations was 0.049 part per million (ppm) for SO₂, 0.6088 ppm for CO, 0.0211 ppm for O₃, 0.0259 ppm for NO₂, and 50.53 μ g/m³ for PM₁₀. In the Spearman rank correlation analysis using the average annual concentrations after the symptom date, most air pollutants showed a positive correlation (r = 0.178-0.467); however, O_3 , and other air pollutants, showed a negative correlation (r = -0.265--0.609; Figure 2). After mixed-effect regression model analysis, no difference was observed for most air pollutants except PM₁₀, which was associated with increased incidence of STEMI compared with NSTEMI for each 1 µg/m³ increase (odds ratio [OR]:1.009, 95% Confidence Interval [CI]: 1.002–1.016; p=0.012; Table 3). For in-hospital cardiogenic shock complication, each 1 µg/m³ increase of PM₁₀ and each 1 part per billion (ppb) increase of SO_2 were associated with increased risk: PM_{10} (OR:1.033, 95% CI: 1.018–1.050; p<0.001),

SO₂ (OR:1.104, 95% CI: 1.006–1.212; p=0.037), respectively. In contrast, for each 1 ppb increase in O₃ was negatively correlated with cardiogenic shock (OR, 0.891; 95% CI:0.857–0.928; p<0.001; Table 4).

When STEMI and each air pollutant were analyzed in subgroups, the results showed there was a significant association with a decrease in STEMI incidence for every 1 ppb increase of NO₂ in CVA patients. In the absence of HTN, there was an increase in STEMI incidence for every 1 μ g/m³ increase PM₁₀ (Figure S1–5). In subgroup analyses used to evaluate the risk of cardiogenic shock with AP exposure, it is shown that there was a significant association between increasing cardiogenic shock complication rate and for each 1 ppb increase of NO₂ in patients with no history of PCI, for each 1 μ g/m³ increase of PM₁₀ in patients with prior IHD or without PCI treatment, and for each 1 ppb increase in SO₂ with HF

Discussion

patients or prior IHD (Figure S6–10).

212

213

214

215

216

217

218

219

220

221

222

223

224

225 We performed a large registry-based analysis to evaluate the association between 226 long-term exposure to AP. In this study, using a nationwide prospective clinical registry, we 227 found that increased concentrations of AP increased the risk of STEMI compared with that of 228 NSTEMI and increased the risk of cardiogenic shock complication, which is related to overall 229 mortality. The results of this study showed that long-term exposure to high levels of PM₁₀ is 230 associated with an increased risk of STEMI. Moreover, this study demonstrates that PM₁₀ and 231 SO₂ may impact on the development of cardiogenic shock complication in patients with AMI. 232 Air pollutants comprise complex mixtures that are compounded with gases, including SO₂, NO₂, CO, O₃, and PM, including PM₁₀ and PM_{2.5}. Although it may intuitively seem 233 234 that AP poses a health risk mostly in the form of respiratory disease, many epidemiological 235 and clinical studies have suggested that the majority of the adverse effects of AP are

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

associated with the cardiovascular system. 16-18 Previous studies demonstrad that AP exposure is associated with endothelial injury and inflammation, indicating that it can trigger cardiovascular events. 19-21 Regarding the association between AP and CVD, many studies have demonstrated that short-term exposure to AP increases the incidence of an acute coronary syndrome (ACS). 22-24 In contrast, the present study investigated the effects of long-term exposure to AP, which was the major novelty of our research. The number of studies on the long-term effects of AP exposure are increasing. The ESCAPE (European Study of Cohorts for Air Pollution Effects) study, the increase in PM₁₀ and PM_{2.5} during the long-term follow-up period increases the risk of ACS. 25 However, these studies mainly focus on mortality or overall clinical outcome. 17, 25-27 Researchers have rarely compared the risk of developing STEMI with that of NSTEMI. To the best of our knowledge, this is the first study to demonstrate a long-term association between AP exposure and the relative incidence of STEMI compared with that of NSTEMI in the Asia-Pacific region. Our present study was shown that the risk of developing STEMI increased compared to NSTEMI according to the 1-year average PM₁₀ concentration before symptom onset. These results indicate that STEMI contributes more than NSTEMI to an increased risk of MI according to the AP concentration. Studies on short-term exposure have reported that elevated AP exposure highly triggers the development of STEMI compared with that of NSTEMI. 28, 29 However, some studies have also reported greater incidence of NSTEMI than that of STEMI due to AP exposure³⁰. The inconsistent results can be attributed to differences in exposure periods, geographic location, pollutant concentration level, study population, and statistical methods used for analysis.^{8, 10} In addition, this study are meaningful in that we clarified the effect of AP exposure on the risk of severe complications of cardiogenic shock. Our main findings showed that an

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

increased AP concentration was associated with an increase incidence of cardiogenic shock complication. Cardiogenic shock occurs in approximately 5–13% of AMI patients.³¹ Moreover, AMI itself was an important etiology contributing to 80% incidences of cardiogenic shock.³² Cardiogenic shock is associated with poor prognosis for high rate of adverse events even with appropriate treatment, with an in-hospital mortality of 20-40% and a 1-year mortality rate of up to 50%. 31 Although the pathophysiology of cardiogenic shock is not fully understood, it is known that the systemic inflammatory response, release of inflammatory cytokines, and increase in the concentration of nitric oxide (NO) are involved in inappropriate vasodilation after peripheral vascular constriction to compensate for the reduction in myocardial contractility.³³, ³⁴ Exposure to AP is related to oxidative stress and systemic inflammation ^{14, 16-18} and it adversely affects vascular homeostasis through the production of superoxide and the uncoupling of NO synthase.³⁵ These results add evidence for the development of cardiogenic shock and its subsequent poor prognosis. In our previously published study, the 1-year average AP concentration before the onset of symptoms was associated with an increase in 30-day short-term mortality. 13 Studies using the same registry reported that in the STEMI group, there was a higher incidence of short-term mortality and cardiogenic shock compared with the incidence found in the NSTEMI group, which is highly correlated with an increase in the risk of cardiac death. ^{31,36} This study strongly suggests that reducing exposure to high concentrations of AP, not only in the high-risk group but also in the low-risk group of AMI, is necessary to reduce the occurrence of potential MI and mortality, even if STEMI appears to be relatively safe because of its younger age and lower co-morbidity rates than NSTEMI. These efforts should be accompanied by policy strategies and clinical practice.

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

This study has several limitations. First, because of the limited sampling data available for PM_{2.5}, the associations with clinical events may have been relatively low. Exposure data for PM_{2.5}, were available for only one year, 2015, the last year of this research period. Evidence suggests that PM size is related to cardiovascular morbidity and mortality.²⁷, ³⁷ Further studies with new data are needed to evaluate the impact of PM_{2.5} in AMI patients in the future with our KAMIR data with later than 2015 registry database. Second, because the patients' addresses were not available, the direct exposure level determined for the patients could be incorrect. It was assumed that patients were admitted to a nearby emergency room at the time of symptom onset. However, some patients who visited other local hospitals or were transferred may have been misclassified, requiring careful interpretation of the results. Third, because of the limitations of the study design, although confounding factors were adjusted for, the results for residential addresses and socioeconomic variables should be carefully considered. We aimed to assess adjusted adequate variables which could be potentially relevant factors using a multivariable model. Finally, although data used in this research were collected by the attending hospitals well-trained, multicenter registry is need to interpret with consideration for several characteristics such as a gap among each hospitals and data such as input errors and misclassification. In conclusion, we observed that high concentration of air pollutants, particularly of PM₁₀, which is an environmental risk factor was associated with an increased incidence of STEMI. Moreover, PM₁₀ and SO₂ levels were risk factors for in-hospital cardiogenic shock complication after MI. This study emphasizes on the need of developing a policy-level strategy and clinical efforts to reduce AP exposure and prevent the incidence of STEMI and severe cardiovascular complications.

Reference

- Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019. *Lancet*. 2020;396:1204-1222
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al.
 Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from
 the gbd 2019 study. J Am Coll Cardiol. 2020;76:2982-3021
- 316 3. Zhao D. Epidemiological features of cardiovascular disease in asia. *JACC Asia*. 2021;1:1-13
- World Health Organization. Regional Office for the Western P. Health at a glance:
 Asia/pacific 2014: Measuring progress towards universal health coverage. Paris:
 OECD Publishing; 2014.
- von Klot S, Peters A, Aalto P, Bellander T, Berglind N, D'Ippoliti D, et al. Ambient
 air pollution is associated with increased risk of hospital cardiac readmissions of
 myocardial infarction survivors in five european cities. *Circulation*. 2005;112:3073-3079
- Warburton DER, Bredin SSD, Shellington EM, Cole C, de Faye A, Harris J, et al. A systematic review of the short-term health effects of air pollution in persons living with coronary heart disease. *Journal of Clinical Medicine*. 2019;8:274
- Shah AS, Langrish JP, Nair H, McAllister DA, Hunter AL, Donaldson K, et al.
 Global association of air pollution and heart failure: A systematic review and meta-analysis. *Lancet*. 2013;382:1039-1048
- Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. *Circulation*. 2001;103:2810-2815
- Europe WHOROf. Review of evidence on health aspects of air pollution revihaap
 project: Technical report. Copenhagen: WHO Regional Office for Europe
- © World Health Organization 2013.; 2013. 336 10. Pope CA, 3rd, Muhlestein JB, May HT, Renlund DG, Ar
- 336 10. Pope CA, 3rd, Muhlestein JB, May HT, Renlund DG, Anderson JL, Horne BD.
 337 Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. *Circulation*. 2006;114:2443-2448
- Chen R, Jiang Y, Hu J, Chen H, Li H, Meng X, et al. Hourly air pollutants and acute coronary syndrome onset in 1.29 million patients. *Circulation*. 2022;145:1749-1760
- Lee MW, Choi BG, Kim SW, Rha SW, Shim MS, Kim DJ, et al. Air pollution and short-term clinical outcomes of patients with acute myocardial infarction. *Clin Exp Pharmacol Physiol.* 2017;44:631-638
- Choi SY, Rha SW, Cha J, Byun JK, Choi BG, Jeong MH. Association of air pollution and 1-year clinical outcomes of patients with acute myocardial infarction. *PLoS One*.
 2022;17:e0272328
- Kim JH, Chae SC, Oh DJ, Kim HS, Kim YJ, Ahn Y, et al. Multicenter cohort study of acute myocardial infarction in korea interim analysis of the korea acute myocardial infarction registry-national institutes of health registry. *Circ J.* 2016;80:1427-1436
- 350 15. Pope Iii CA, Dockery DW. Health effects of fine particulate air pollution: Lines that
 351 connect. Journal of the Air & Waste Management Association (Air & Waste Management Association). 2006;56:709-742
- 353 16. Brook RD, Rajagopalan S, Pope CA, 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, et al. Particulate matter air pollution and cardiovascular disease: An update to the
- scientific statement from the american heart association. *Circulation*. 2010;121:2331-2378

- 357 17. Pope CA, 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, et al.
- 358 Cardiovascular mortality and long-term exposure to particulate air pollution:
- Epidemiological evidence of general pathophysiological pathways of disease. *Circulation*. 2004;109:71-77
- 361 18. Kampa M, Castanas E. Human health effects of air pollution. *Environ Pollut*. 2008;151:362-367
- 363 19. Krishnan RM, Adar SD, Szpiro AA, Jorgensen NW, Van Hee VC, Barr RG, et al.
 364 Vascular responses to long- and short-term exposure to fine particulate matter: Mesa
 365 air (multi-ethnic study of atherosclerosis and air pollution). *J Am Coll Cardiol*.
 366 2012;60:2158-2166
- 367 20. Bind MA, Baccarelli A, Zanobetti A, Tarantini L, Suh H, Vokonas P, et al. Air pollution and markers of coagulation, inflammation, and endothelial function:

 Associations and enigene-environment interactions in an elderly cohort. Enidem
- Associations and epigene-environment interactions in an elderly cohort. *Epidemiology*. 2012;23:332-340
- Pope CA, 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O'Toole T.
 Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation. *Circ Res.* 2016;119:1204-1214
- 374 22. Akbarzadeh MA, Khaheshi I, Sharifi A, Yousefi N, Naderian M, Namazi MH, et al.
 375 The association between exposure to air pollutants including pm(10), pm(2.5), ozone,
 376 carbon monoxide, sulfur dioxide, and nitrogen dioxide concentration and the relative
 377 risk of developing stemi: A case-crossover design. *Environ Res.* 2018;161:299-303
- 378 23. Mustafic H, Jabre P, Caussin C, Murad MH, Escolano S, Tafflet M, et al. Main air pollutants and myocardial infarction: A systematic review and meta-analysis. *Jama*. 2012;307:713-721
- Nuvolone D, Balzi D, Chini M, Scala D, Giovannini F, Barchielli A. Short-term association between ambient air pollution and risk of hospitalization for acute myocardial infarction: Results of the cardiovascular risk and air pollution in tuscany (riscat) study. *Am J Epidemiol*. 2011;174:63-71
- 25. Cesaroni G, Forastiere F, Stafoggia M, Andersen ZJ, Badaloni C, Beelen R, et al.
 Long term exposure to ambient air pollution and incidence of acute coronary events:
 Prospective cohort study and meta-analysis in 11 european cohorts from the escape project. *BMJ*. 2014;348:f7412
- Tonne C, Wilkinson P. Long-term exposure to air pollution is associated with survival following acute coronary syndrome. *Eur Heart J.* 2013;34:1306-1311
- 391 27. Miller KA, Siscovick DS, Sheppard L, Shepherd K, Sullivan JH, Anderson GL, et al.
 392 Long-term exposure to air pollution and incidence of cardiovascular events in women.
 393 N Engl J Med. 2007;356:447-458
- Pope CA, Muhlestein JB, Anderson JL, Cannon JB, Hales NM, Meredith KG, et al.
 Short-term exposure to fine particulate matter air pollution is preferentially associated with the risk of st-segment elevation acute coronary events. *J Am Heart Assoc*. 2015;4
- 397 29. Gardner B, Ling F, Hopke PK, Frampton MW, Utell MJ, Zareba W, et al. Ambient 398 fine particulate air pollution triggers st-elevation myocardial infarction, but not non-st 399 elevation myocardial infarction: A case-crossover study. *Part Fibre Toxicol*. 400 2014;11:1
- 401 30. Ho AFW, Zheng H, Earnest A, Cheong KH, Pek PP, Seok JY, et al. Time-stratified 402 case crossover study of the association of outdoor ambient air pollution with the risk 403 of acute myocardial infarction in the context of seasonal exposure to the southeast 404 asian haze problem. *J Am Heart Assoc*. 2019;8:e011272

- 405 31. Backhaus T, Fach A, Schmucker J, Fiehn E, Garstka D, Stehmeier J, et al.
- Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute st-segment elevation myocardial infarction: Results from the
- bremen stemi registry. Clin Res Cardiol. 2018;107:371-379
- 409 32. Harjola VP, Lassus J, Sionis A, Køber L, Tarvasmäki T, Spinar J, et al. Clinical
 410 picture and risk prediction of short-term mortality in cardiogenic shock. *Eur J Heart* 411 *Fail*. 2015;17:501-509
- 412 33. Vahdatpour C, Collins D, Goldberg S. Cardiogenic shock. *Journal of the American Heart Association*. 2019;8:e011991
- 414 34. Diepen Sv, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al.
- Contemporary management of cardiogenic shock: A scientific statement from the american heart association. *Circulation*. 2017;136:e232-e268
- Cherng TW, Paffett ML, Jackson-Weaver O, Campen MJ, Walker BR, Kanagy NL.
 Mechanisms of diesel-induced endothelial nitric oxide synthase dysfunction in
 coronary arterioles. *Environmental Health Perspectives*. 2011;119:98-103
- 420 36. Park HW, Yoon CH, Kang SH, Choi DJ, Kim HS, Cho MC, et al. Early- and late-421 term clinical outcome and their predictors in patients with st-segment elevation
- myocardial infarction and non-st-segment elevation myocardial infarction. *Int J Cardiol.* 2013;169:254-261
- 424 37. Crouse DL, Peters PA, van Donkelaar A, Goldberg MS, Villeneuve PJ, Brion O, et al.
 425 Risk of nonaccidental and cardiovascular mortality in relation to long-term exposure
 426 to low concentrations of fine particulate matter: A canadian national-level cohort
- 427 study. *Environ Health Perspect*. 2012;120:708-714 428

Acknowledgements

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

This study was done with the support of Korean Circulation Society (KCS) to commemorate the 50th Anniversary of KCS. The KAMIR study group of the KSC was as follows: Korea University Guro Hospital, Seoul, Korea (Seung-Woon Rha), Gachon University Gil Medical Center, Incheon, Korea (Tae Hoon Ahn), Wonju Severance Christian Hospital, Wonju, Korea (Junghan Yoon), Seoul National University Hospital, Seoul, Korea (Hyo-Soo Kim), Seoul St. Mary's Hospital, Seoul, Korea (Ki-Bae Seung), Samsung Medical Center, Seoul, Korea (Hyeon-Cheol Gwon), Kyungpook National University Hospital, Daegu, Korea (Shung Chull Chae), Kyung Hee University Hospital at Gangdong, Seoul, Korea (Chong-Jin Kim), Pusan National University Hospital, Busan, Korea (Kwang Soo Cha), Yeungnam University Medical Center, Daegu, Korea (Jung-Hee Lee), Jeonbuk National University Hospital, Jeonju, Korea (Jei Keon Chae), Jeju National University Hospital, Jeju, Korea (Seung-Jae Joo), Seoul National University Bundang Hospital, Seongnam, Korea (Chang-Hwan Yoon), Keimyung University Dongsan Medical Center, Daegu, Korea (Seung-Ho Hur), Chungnam National University Hospital, Daejeon, Korea (In-Whan Seong), Chungbuk National University Hospital, Cheongju, Korea (Kyung-Kuk Hwang), Inje University Haeundae Paik Hospital, Busan, Korea (Doo-Il Kim), Wonkwang University Hospital, Iksan, Korea (Seok Kyu Oh), Gyeongsang National University Hospital, Jinju, Korea (Jin-Yong Hwang), and Chonnam National University Hospital, Gwangju, Korea (Myung Ho Jeong).

Sources of Funding

This research was supported by grants (2020ER630800 and 2022ER090900) from the Korea Centers for Disease Control and Prevention. (https://www.kdca.go.kr/). The funding organization had no role in the design and administration of the study; the collection,

- 452 management, analysis, and interpretation of the data; the preparation, review, or approval of
- 453 the manuscript; nor the decision to submit the manuscript for publication.
- 454 Disclosures
- 455 None.

- 456 **Supplemental Material**
- 457 Figures S1–S10

-17-

459 Tables

460

461

462

463 464

465

Table 1. Baseline characteristics

Variables	Total	NSTEMI (n=20,526)	STEMI (n=25,093)	P value
Age (year)	63.82 ± 12.77	65.10 ± 12.40	62.77 ± 12.97	< 0.001
Sex (male)	32,921 (72.2)	14,042 (68.4)	18,879 (75.2)	< 0.001
Body Mass Index (kg/m²)	23.98 ± 3.25	23.94 ± 3.27	24.01 ± 3.23	0.036
Systolic Blood Pressure (mmHg)	129.69 ± 28.25	133.71 ± 27.38	126.37 ± 28.53	< 0.001
Diastolic Blood Pressure (mmHg)	78.89 ± 16.66	80.18 ± 15.87	77.82 ± 17.22	< 0.001
Heart Rate (bpm)	78.19 ± 19.90	79.70 ± 19.36	76.96 ± 20.25	< 0.001
Left Ventricular Ejection Fraction (%)	51.96 ± 11.86	53.51 ± 12.20	50.66 ± 11.41	< 0.001
Killip Class 4	2,389 (5.2)	552 (2.7)	1,837 (7.3)	< 0.001
Hypertension	22,776 (49.9)	11,203 (54.6)	11,573 (46.1)	< 0.001
Diabetes Mellitus	12,596 (27.6)	6,418 (31.3)	6,178 (24.6)	< 0.001
Dyslipidemia	5,082 (11.1)	2,571 (12.5)	2,511 (10.0)	< 0.001
Cerebrovascular Disease	3,030 (6.6)	1,659 (8.1)	1,371 (5.5)	< 0.001
Heart Failure	842 (1.8)	582 (2.8)	260 (1.0)	< 0.001
Smoking History	26,337 (57.7)	11,077 (54.0)	15,260 (60.8)	< 0.001
Current Smoker	18,853 (41.3)	7,276 (35.4)	11,577 (46.1)	< 0.001
Family History of Heart Disease	3,285 (7.2)	1,501 (7.3)	1,784 (7.1)	0.404
Previous Ischemic Heart Disease	7,027 (15.4)	4,150 (20.2)	2,877 (11.5)	< 0.001
Previous PCI	3,346 (7.3)	1,968 (9.6)	1,378 (5.5)	< 0.001
Previous MI	2,164 (4.7)	1,265 (6.2)	899 (3.6)	< 0.001
Previous CABG	371 (0.8)	268 (1.3)	103 (0.4)	< 0.001
Previous Angina	2,793 (6.1)	1,733 (8.4)	1,060 (4.2)	< 0.001
Initial treatment of MI				
Thrombolysis	990 (2.2)	0 (0.0)	990 (3.9)	< 0.001
CABG	933 (2.0)	556 (2.7)	377 (1.5)	< 0.001
PCI	39,847 (87.3)	16,329 (79.6)	23,518 (93.7)	< 0.001
Multi-Vessel Disease	21,542 (47.2)	9,942 (48.4)	11,600 (46.2)	< 0.001
Left Main Disease	1,661 (3.6)	957 (4.7)	704 (2.8)	< 0.001
Infarct-related artery				
Left Main	886 (1.9)	522 (2.5)	364 (1.5)	< 0.001
Left Anterior Descending Artery	18,963 (41.6)	6,987 (34.0)	11,976 (47.7)	< 0.001
Left Circumflex Artery	6,849 (15.0)	4,596 (22.4)	2,253 (9.0)	< 0.001
Right Coronary Artery	13,489 (29.6)	4,719 (23.0)	8,770 (34.9)	< 0.001
Cardiogenic Shock Complications	2,317 (5.1)	554 (2.7)	1,763 (7.0)	< 0.001

Data is expressed as number (percentage), mean \pm standard deviation.

CABG, coronary artery bypass grafting; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; MI, myocardial infarction; STEMI, ST-elevation myocardial infarction

Table 2. Distribution for annual average air pollution concentration before symptom date.

467

468

469

	SO ₂ (ppm)	CO (ppm)	O ₃ (ppm)	NO ₂ (ppm)	$PM_{10} \left(\mu g/m^{s}\right)$
Min.	0.0014	0.2028	0.0037	0.0070	18.25
Q1	0.0041	0.5312	0.0176	0.0218	44.65
Median	0.0049	0.6088	0.0211	0.0259	50.53
Q3	0.0061	0.7211	0.0244	0.0342	58.67
Max.	0.0136	1.4976	0.0437	0.0812	99.14
IQR	0.0020	0.1899	0.0068	0.0124	14.02
Mean	0.0053	0.6276	0.0210	0.0284	52.57

CO, carbon monoxide; IQR, interquartile range; NO₂, nitric dioxide; O₃, ozone; PM₁₀, particulate matter 10 µm or less in diameter; ppm, part per million; Q1, 1st quintile; Q3, 3rd quintile. SO₂, sulfur dioxide.

Table 3. Univariate and multivariate regression analysis of the incidence of STEMI compared with NSTEMI regarding annual average concentration of each air pollutant before symptom date.

	Univariate		Multivariate		
	OR (95% CI)	P value	OR (95% CI)	P value	
SO ₂ (ppb)	1.044 (0.998 - 1.093)	0.060	1.041 (0.995 - 1.089)	0.084	
CO (ppm)	1.037 (0.978 - 1.100)	0.225	1.036 (0.977 - 1.099)	0.236	
O ₃ (ppb)	0.990 (0.972 - 1.009)	0.293	0.989 (0.971 - 1.007)	0.239	
NO ₂ (ppb)	1.000 (0.987 - 1.012)	0.943	0.999 (0.987 - 1.012)	0.914	
$PM_{10} \left(\mu g/m^3\right)$	1.008 (1.001 - 1.014)	0.027	1.009 (1.002 - 1.016)	0.012	

Adjusted for Age, body mass index, diabetes mellitus, dyslipidemia, heart failure,

hypertension, previous ischemic heart disease, sex, smoking status, stroke, symptom onset.

CI, confidence interval; CO, carbon monoxide; NO₂, nitric dioxide; O₃, ozone; OR, odds ratio;

PM₁₀, particulate matter 10 μm or less in diameters; ppb, part per billion; ppm, part per

million; SO₂, sulfur dioxide.

470

471

472

473

474

476 477

478

Table 4. Univariate and multivariate regression analysis between the incidence of cardiogenic shock events and the annual average concentration of each air pollutant before the symptom date of myocardial infarction.

	Univariate		Multivariate	<u>;</u>
	OR (95% CI)	P value	OR (95% CI)	P value
SO ₂ (ppb)	1.122 (1.021 - 1.234)	0.017	1.104 (1.006 - 1.212)	0.037
CO (ppm)	1.090 (0.960 - 1.238)	0.182	1.076 (0.949 - 1.219)	0.254
O ₃ (ppb)	0.889 (0.853 - 0.926)	< 0.001	0.891 (0.857 - 0.928)	< 0.001
NO ₂ (ppb)	1.013 (0.985 - 1.041)	0.365	1.015 (0.988 - 1.042)	0.269
$PM_{10} \left(\mu g/m^3\right)$	1.036 (1.019 - 1.053)	< 0.001	1.033 (1.018 - 1.050)	< 0.001

Adjusted for age, body mass index, diabetes mellitus, dyslipidemia, heart failure, hypertension, left ventricular ejection fraction, percutaneous coronary intervention, previous ischemic heart disease, sex, smoking status, STEMI status, stroke, and symptom date. CI, confidence interval; CO, carbon monoxide; NO₂, nitric dioxide; O₃, ozone; OR, odds ratio; PM₁₀, particulate matter 10 µm or less in diameter; ppb, part per billion; ppm, part per million; SO₂, sulfur dioxide.

Figures and Figure Legends

491

492

493 494 495




Figure 1. Study flow chart of patient enrollment. AMI, acute myocardial infarction; KAMIR, Korea Acute Myocardial Infarction Registry; MI, myocardial infarction




Figure 2. Spearman correlation coefficients for annual average concentrations of air pollutants. CO, carbon monoxide; NO_2 , nitric dioxide; PM_{10} , particulate matter 10 μm or less in diameter.

499

500

Supplemental data

502

503

504

505

506

507

Figure S1. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the incidence of STEMI compared with NSTEMI according to an increase of 1 part per billion SO₂ before the onset of symptoms.




Figure S2. Subgroup analysis for adjusted odds ratio and 95% confidence interval of the incidence of STEMI compared with NSTEMI according to an increase of 0.1 part per million CO




Figure S3. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the incidence of STEMI compared with NSTEMI according to an increase of 1 part per billion O₃ before the onset of symptoms.




Figure S4. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the incidence of STEMI compared with NSTEMI according to an increase of 1 part per billion NO₂ before the onset of symptoms.




Figure S5. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the incidence of STEMI compared with NSTEMI according to an increase of 1 μ g/m³ PM₁₀ before the the symptom date.




Figure S6. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the incidence of in-hospital cardiogenic shock according to an increase of 1 part per billion SO₂ before symptom onset.

529

530

531




Figure S7. Subgroup Analysis for adjusted odds ratio and 95% confidence interval of the incidence of in-hospital cardiogenic shock according to an increase of 0.1 part per million CO before symptom date.

534

535

536




Figure S8. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the

incidence of in-hospital cardiogenic shock according to an increase of 1 part per billion O₃.

538

539

540

Variables	Numbers	Odds Ratio (95% CI)	P value	P int
Age				0.027
≥ 65 years	22479	0.888 [0.850	- 0.928] < 0.001	
< 65 years	23140	0.916 [0.882	- 0.951] < 0.001	
Sex		1		0.801
Male	32921	0.893 [0.858	-0.929] <0.001	
Female	12698	0.909 [0.870	-0.951] <0.001	
Hypertension				0.509
Yes	22776	0.906 [0.873	- 0.941] < 0.001	
No	22843	0.890 [0.849	- 0.933] < 0.001	
Diabetes				0.100
Yes	12596	0.890 [0.853	-0.929] <0.001	
No	33023	0.903 [0.867	- 0.941] < 0.001	
Dyslipidemia			1.5	0.276
Yes	5082	0.929 [0.884	- 0.976] 0.003	
No	40537	0.891 [0.856		
CVA		!		0.608
Yes	3030	0.934 [0.890	- 0.980] 0.006	
No	42589	0.892 [0.856		
Heart failure		1		0.624
Yes	842	0.935 [0.882	0.023	0.02
No	44777	0.891 [0.857	[[[마다 : 10 10 10 10 10 10 10 10 10 10 10 10 10	
Prior IHD	44777	1 0.051 [0.057	0.527]	0.145
Yes	7027	0.906 [0.868	- 0.946] < 0.001	0.1.10
No	38592	0.895 [0.859		
Smoking	50572	- 0.055 [0.055	0.554]	0.166
Yes	18853	0.909 [0.873	- 0.946] < 0.001	0.100
No	26766	0.890 [0.854		
Family history of C		0.050 (0.054	0.525]	0.325
Yes	3285	0.965 [0.913	- 1.020] 0.208	0.020
No	42334	0.891 [0.857	,	
STEMI	42554	0.871 [0.857	0.727] 40.001	0.868
Yes	25093	0.897 [0.864	- 0.932] < 0.001	0.000
No	20526	0.899 [0.856		
PCI	20320	0.899 [0.830	0.945] \0.001	< 0.00
Yes	39847	0.901 [0.865	- 0.938] < 0.001	~0.00
No	5772	0.901 [0.865	,	
LVEF	3112	0.865 [0.816	0.917] 50.001	0.986
	20402	0.011 (0.076	0.0461 <0.001	0.986
≥ 50%	29402	0.911 [0.876	,	
< 50%	16217	0.883 [0.843	- 0.925] <0.001	

Figure S9. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the

incidence of in-hospital cardiogenic shock according to an increase of 1 part per billion NO₂.

542

543

544




Figure S10. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the incidence of in-hospital cardiogenic shock according to the increase 1 μ g/m³ PM₁₀ before the symptom date.

547

548

